The Vanguard Health Care Fund (Trades, Portfolio) sold shares of the following stocks during the second quarter of 2020.
Eli Lilly
The fund reduced its position in Eli Lilly and Co. (LLY) by 22.16%. The trade had an impact of -1.05% on the portfolio.
The pharmaceutical company has a market cap of $146.34 billion and an enterprise value of $161.91 billion.
GuruFocus gives the company a profitability and growth rating of 8 out of 10. The return on equity of 193.08% and return on assets of 14.19% are outperforming 91% of companies in the drug manufacturers industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 0.1 is below the industry median of 0.87.
The largest guru shareholder of the company is PRIMECAP Management (Trades, Portfolio) with 4.38% of outstanding shares, followed by Vanguard Health Care Fund (Trades, Portfolio) with 1.10% and Spiros Segalas (Trades, Portfolio) with 0.47%.
Vertex Pharmaceuticals
The fund reduced its Vertex Pharmaceuticals Inc. (VRTX) stake by 27.52%. The portfolio was impacted by -0.76%.
The company, which develops small-molecule drugs for the treatment of serious diseases, has a market cap of $72.44 billion and an enterprise value of $68.78 billion.
GuruFocus gives the company a profitability and growth rating of 5 out of 10. The return on equity of 27.38% and return on assets of 19.72% are outperforming 97% of companies in the biotechnology industry. Its financial strength is rated 8 out of 10. The cash-debt ratio of 7.86 is below the industry median of 8.32.
The largest guru shareholder of the company is Jim Simons (Trades, Portfolio)’ Renaissance Technologies with 2.65% of outstanding shares, followed by Segalas with 0.69% and Pioneer Investments (Trades, Portfolio) with 0.20%.
Chugai Pharmaceutical
The fund's Chugai Pharmaceutical Co Ltd.’s (TSE:4519) position was trimmed by 25.65%. The portfolio was impacted by -0.67%.
Merck & Co
The investment fund cut its holding in Merck & Co. Inc. (MRK) by 34.54%. The trade had an impact of -0.59% on the portfolio.
The pharmaceutical products manufacturing company has a market cap of $199.38 billion and an enterprise value of $220.04 billion.
GuruFocus gives the company a profitability and growth rating of 8 out of 10. The return on equity of 37.82% and return on assets of 12.11% are outperforming 88% of companies in the drug manufacturers industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 0.27 is below the industry median of 0.87.
Some notable guru shareholders are Ken Fisher (Trades, Portfolio) with 0.35% of outstanding shares, Pioneer Investments (Trades, Portfolio) with 0.30% and Simons’ firm with 0.27%.
Medtronic
The fund curbed its position in Medtronic PLC (MDT) by 16.24%, impacting the portfolio by -0.46%.
The retailer of pharmaceutical products has a market cap of $129.40 billion and an enterprise value of $143.38 billion.
GuruFocus gives the therapeutic medical devices manufacturer a profitability and growth rating of 8 out of 10. The return on equity of 9.44% and return on assets of 5.26% are outperforming 69% of companies in the medical devices and instruments industry. Its financial strength is rated 6 out of 10. The cash-debt ratio of 0.44 is below the industry median of 1.65.
Some notable guru shareholders are Barrow, Hanley, Mewhinney & Strauss with 0.55% of outstanding shares, Pioneer Investments (Trades, Portfolio) with 0.55 and Dodge & Cox with 0.42%.
Zimmer
The investment fund trimmed its holding in Zimmer Biomet Holdings Inc. (ZBH) by 66.1%. The trade had an impact of -0.42% on the portfolio.
The company, which manufactures orthopedic reconstructive implants, has a market cap of $28.60 billion and an enterprise value of $35.85 billion.
GuruFocus gives the company a profitability and growth rating of 8 out of 10. The return on equity of 3.17% and return on assets of 1.53% are outperforming 54% of companies in the medical devices and instruments industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 0.25 is below the industry median of 1.65.
The largest guru shareholder of the company is PRIMECAP Management (Trades, Portfolio) with 1.65% of outstanding shares, followed by Pioneer Investments (Trades, Portfolio) with 1.36% and HOTCHKIS & WILEY with 0.97%.
Qiagen
The exited its Qiagen NV (QGEN) position. The trade had an impact of -0.38% on the portfolio.
The company has a market cap of $11.50 billion and an enterprise value of $12.47 billion.
GuruFocus gives the company a profitability and growth rating of 6 out of 10. While the return on equity of -1.22% is underperforming the sector, return on assets of -0.59% is outperforming 53% of companies in the medical diagnostics and research industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 0.44 is below the industry median of 1.51.
Some notable gurus shareholders are PRIMECAP Management (Trades, Portfolio) with 6.28% of outstanding shares, Pioneer Investments (Trades, Portfolio) with 1.22% and Jeremy Grantham (Trades, Portfolio) with 0.53%.
Seattle Genetics
The investment fund cut its holding in Seattle Genetics Inc. (SGEN) by 41.3%. The trade had an impact of -0.34% on the portfolio.
The biotech firm has a market cap of $29.62 billion and an enterprise value of $28.90 billion.
GuruFocus gives the company a profitability and growth rating of 3 out of 10. The return on equity of -19.59% and return on assets of -16.42% are outperforming 69% of companies in the biotechnology industry. Its financial strength is rated 7 out of 10. The cash-debt ratio of 10.67 is above the industry median of 8.32.
Other notable shareholders include Steven Cohen (Trades, Portfolio)’s Point72 Asset Management with 0.16% of outstanding shares and Pioneer Investments (Trades, Portfolio) with 0.02%.
Disclosure: I do not own any stocks mentioned.
Read more here:
- 5 Bargain Stocks With High Dividend Yields
- Insiders Roundup: Tetraphase Pharmaceuticals, Bank of America
- 5 Bargain Stocks With High Profitability
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
